{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:15:00Z","timestamp":1793315700541,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04156-8","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T08:15:49Z","timestamp":1754554549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Predictive factors for metabolic syndrome in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)"],"prefix":"10.1186","volume":"25","author":[{"given":"Mohammad","family":"Alnees","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Awwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duha","family":"Najajra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalaziz","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Heih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thara","family":"Al-Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar Abu","family":"Hamdeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawthar","family":"Jarrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Al-Ihribat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Salloum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qusay","family":"Abdoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitham Abu","family":"Khadija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"issue":"3","key":"4156_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","volume":"32","author":"WK Chan","year":"2023","unstructured":"Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated steatotic liver disease (MASLD): A State-of-the-Art review. J Obes Metab Syndr. 2023;32(3):197\u2013213.","journal-title":"J Obes Metab Syndr"},{"issue":"1","key":"4156_CR2","doi-asserted-by":"publisher","first-page":"e34934","DOI":"10.1097\/MD.0000000000034934","volume":"103","author":"KCv Son","year":"2024","unstructured":"Son KCv, Nijenhuis-Noort LCt, Boone SC, Mook-Kanamori DO, Holleboom AG, Roos PR, et al. Prevalence of metabolic Dysfunction-Associated steatotic liver disease (MASLD) in a Middle-Aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies. Medicine. 2024;103(1):e34934.","journal-title":"Medicine"},{"issue":"10","key":"4156_CR3","doi-asserted-by":"publisher","first-page":"e47240","DOI":"10.7759\/cureus.47240","volume":"15","author":"F Zahoor","year":"2023","unstructured":"Zahoor F, Saeed NU, Javed S, Sadiq HZ, Mand Khan F, Haider M, Shafqat MN, Maqbool A, Chaudhry A. Association of metabolic Dysfunction-Associated steatotic liver disease\/Non-alcoholic fatty liver disease with type 2 diabetes mellitus: A Case-Control study in a tertiary care hospital in Pakistan. Cureus. 2023;15(10):e47240. https:\/\/doi.org\/10.7759\/cureus.47240. PMID: 38021965; PMCID: PMC10654449.","journal-title":"Cureus"},{"issue":"11\u201312","key":"4156_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/1751-2980.13325","volume":"25","author":"Y Inukai","year":"2024","unstructured":"Inukai Y, Ito T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, et al. Type 2 diabetes and hypertension as risk factors for advanced fibrosis in biopsy proven metabolic Dysfunction\u2013Associated steatotic liver disease. J Dig Dis. 2024;25(11\u201312):685\u201393.","journal-title":"J Dig Dis"},{"issue":"9","key":"4156_CR5","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1111\/dom.15723","volume":"26","author":"C Aernouts","year":"2024","unstructured":"Aernouts C, Beld\u00e9 SPW, Lambrechts J, Mertens J, Ledeganck KJ, Francque S, et al. Metabolic Dysfunction-associated steatotic liver disease is associated with worse time in ranges in type 1 diabetes. Diabetes Obes Metab. 2024;26(9):3781\u201390.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"4156_CR6","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.14309\/ajg.0000000000002796","volume":"119","author":"AS Barritt","year":"2024","unstructured":"Barritt AS, Yu F, Mospan AR, Newsome PN, Roden M, Morris H, et al. High concordance between nonalcoholic fatty liver disease and metabolic Dysfunction-Associated steatotic liver disease in the TARGET-NASH Real-World cohort. Am J Gastroenterol. 2024;119(8):1624\u20137.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"4156_CR7","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque S, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966\u201386.","journal-title":"Hepatology"},{"issue":"6","key":"4156_CR8","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1097\/HEP.0000000000000664","volume":"79","author":"C Lee","year":"2023","unstructured":"Lee C, Yoon EL, Kim M, Kang BK, Cho S, Nah E, et al. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings. Hepatology. 2023;79(6):1393\u2013400.","journal-title":"Hepatology"},{"issue":"17","key":"4156_CR9","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.3748\/wjg.v29.i17.2534","volume":"29","author":"KY Zeng","year":"2023","unstructured":"Zeng KY, Bao WYG, Wang YH, Liao M, Yang J, Huang JY, et al. Non-invasive evaluation of liver steatosis with imaging modalities: new techniques and applications. World J Gastroenterol. 2023;29(17):2534\u201350.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"4156_CR10","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.7150\/thno.40249","volume":"10","author":"AM Pirmoazen","year":"2020","unstructured":"Pirmoazen AM, Khurana A, El Kaffas A, Kamaya A. Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease. Theranostics. 2020;10(9):4277\u201389.","journal-title":"Theranostics"},{"issue":"3","key":"4156_CR11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.rcl.2019.01.003","volume":"57","author":"RG Barr","year":"2019","unstructured":"Barr RG. Ultrasound of diffuse liver disease including elastography. Radiol Clin North Am. 2019;57(3):549\u201362.","journal-title":"Radiol Clin North Am"},{"issue":"40","key":"4156_CR12","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.3748\/wjg.v25.i40.6053","volume":"25","author":"G Ferraioli","year":"2019","unstructured":"Ferraioli G, Soares Monteiro LB. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol. 2019;25(40):6053\u201362.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"4156_CR13","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3390\/bioengineering11060600","volume":"11","author":"A Alizargar","year":"2024","unstructured":"Alizargar A, Chang YL, Alkhaleefah M, Tan TH. Precision Non-Alcoholic fatty liver disease (NAFLD) diagnosis: leveraging ensemble machine learning and gender insights for Cost-Effective detection. Bioengineering. 2024;11(6):600.","journal-title":"Bioengineering"},{"issue":"14","key":"4156_CR14","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.7150\/ijms.62010","volume":"18","author":"C Wang","year":"2021","unstructured":"Wang C, Cai Z, Deng X, Li H, Zhao Z, Guo C, et al. Association of hepatic steatosis index and fatty liver index with carotid atherosclerosis in type 2 diabetes. Int J Med Sci. 2021;18(14):3280\u20139.","journal-title":"Int J Med Sci"},{"issue":"5\u20136","key":"4156_CR15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1242\/dmm.001180","volume":"2","author":"PL Huang","year":"2009","unstructured":"Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2(5\u20136):231\u20137.","journal-title":"Dis Model Mech"},{"issue":"1","key":"4156_CR16","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1002\/edm2.468","volume":"7","author":"G Yousefzadeh","year":"2024","unstructured":"Yousefzadeh G, Sayyadi A, Najafipour H, Sabaghnejad V, Pezeshki S. Comparing the association of two metabolic syndrome definitions, NCEP ATP III and IDF, with the risk of developing atherosclerotic cardiovascular disease: an analytical cross-sectional study. Endocrinol Diabetes Metab. 2024;7(1):e468. https:\/\/doi.org\/10.1002\/edm2.468. PMID: 38268305; PMCID: PMC10794157.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"3","key":"4156_CR17","first-page":"77","volume":"11","author":"RI Orzan","year":"2024","unstructured":"Orzan RI, Gligor RI, Agoston R, Cionca C, Zlibut A, Pais R, et al. Metabolic dysfunction associated liver disease in patients undergoing coronary computed tomography angiography. J Cardiovasc Dev Dis. 2024;11(3):77.","journal-title":"J Cardiovasc Dev Dis"},{"issue":"23","key":"4156_CR18","doi-asserted-by":"publisher","first-page":"7276","DOI":"10.3390\/jcm12237276","volume":"12","author":"J Rivera-Esteban","year":"2023","unstructured":"Rivera-Esteban J, Jim\u00e9nez-Masip A, Mu\u00f1oz S, August\u00edn S, Guerrero R, Gabriel-Medina P, et al. Prevalence and risk factors of MASLD and liver fibrosis amongst the penitentiary population in catalonia: the PRISONAFLD study. J Clin Med. 2023;12(23):7276.","journal-title":"J Clin Med"},{"issue":"19","key":"4156_CR19","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.3390\/healthcare11192696","volume":"11","author":"A Solomon","year":"2023","unstructured":"Solomon A, Negrea MO, Cip\u0103ian CR, Boicean A, Mih\u0103il\u0103 RG, Rezi C, et al. Interactions between metabolic syndrome, MASLD, and arterial stiffening: A Single-Center Cross-Sectional study. Healthcare. 2023;11(19):2696.","journal-title":"Healthcare"},{"issue":"1","key":"4156_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3390\/jcm13010278","volume":"13","author":"P Danpanichkul","year":"2024","unstructured":"Danpanichkul P, Suparan K, Kim D, Wijarnpreecha K. What is new in metabolic Dysfunction-Associated steatotic liver disease in lean individuals: from bench to bedside. J Clin Med. 2024;13(1):278.","journal-title":"J Clin Med"},{"key":"4156_CR21","doi-asserted-by":"publisher","first-page":"1539283","DOI":"10.3389\/fmed.2025.1539283","volume":"12","author":"Z Gao","year":"2025","unstructured":"Gao Z, Deng H, Qin B, Bai L, Li J, Zhang J. Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease. Front Med (Lausanne). 2025;12:1539283. https:\/\/doi.org\/10.3389\/fmed.2025.1539283. PMID: 39911867; PMCID: PMC11794791.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"4156_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1161\/CIRCULATIONAHA.114.014508","volume":"131","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD). Circulation. 2015;131(2):211\u20139.","journal-title":"Circulation"},{"issue":"19","key":"4156_CR23","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.3390\/healthcare11192696","volume":"11","author":"A Solomon","year":"2023","unstructured":"Solomon A, Negrea MO, Cip\u0103ian CR, Boicean A, Mihaila R, Rezi C, et al. Interactions between metabolic syndrome, MASLD, and arterial stiffening: A Single-Center Cross-Sectional study. Healthcare. 2023;11(19):2696.","journal-title":"Healthcare"},{"key":"4156_CR24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2147\/VHRM.S319161","volume":"17","author":"K Haile","year":"2021","unstructured":"Haile K, Haile A, Timerga A. Predictors of lipid profile abnormalities among patients with metabolic syndrome in Southwest ethiopia: A Cross-Sectional study. Vasc Health Risk Manag. 2021;17:461\u20139.","journal-title":"Vasc Health Risk Manag"},{"key":"4156_CR25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/OPTH.S80355","volume":"9","author":"JJ Chen","year":"2015","unstructured":"Chen JJ, Wendel LJ, Birkholz ES, Vallone JG, Coleman AL, Yu F, Mahajan VB. The metabolic syndrome and severity of diabetic retinopathy. Clin Ophthalmol. 2015;9:757\u201364. https:\/\/doi.org\/10.2147\/OPTH.S80355. PMID: 25995613; PMCID: PMC4425343.","journal-title":"Clin Ophthalmol"},{"key":"4156_CR26","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.2147\/DMSO.S265214","volume":"14","author":"Q Sun","year":"2021","unstructured":"Sun Q, Tang L, Zeng Q, Gu M. Assessment for the correlation between diabetic retinopathy and metabolic syndrome: A Cross-Sectional study. Diabetes Metab Syndr Obes. 2021;14:1773\u201381.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"4156_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.diabres.2019.04.022","volume":"153","author":"SM Chuang","year":"2019","unstructured":"Chuang SM, Shih HM, Chien MN, Liu SC, Wang CH, Lee CC. Risk factors in metabolic syndrome predict the progression of diabetic nephropathy in patients with type 2 diabetes. Diabetes Res Clin Pract. 2019;153:6\u201313.","journal-title":"Diabetes Res Clin Pract"},{"key":"4156_CR28","doi-asserted-by":"crossref","unstructured":"Marchesini G, Day CP, Dufour JF, Canbay A, Nobili V, Ratziu V et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol [Internet]. 2016 Jun 1 [cited 2024 Sep 25];64(6):1388\u2013402. Available from: http:\/\/www.journal-of-hepatology.eu\/article\/S0168827815007345\/fulltext","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"4156_CR29","doi-asserted-by":"crossref","unstructured":"Cho KY, Nakamura A, Omori K, Takase T, Miya A, Yamamoto K et al. Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. J Diabetes Investig [Internet]. 2021 Jul 1 [cited 2024 Sep 25];12(7):1272\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33131199\/","DOI":"10.1111\/jdi.13457"},{"key":"4156_CR30","doi-asserted-by":"crossref","unstructured":"Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W et al. Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease. Digestive and Liver Disease [Internet]. 2010 Jul 1 [cited 2024 Sep 25];42(7):503\u20138. Available from: http:\/\/www.dldjournalonline.com\/article\/S1590865809003363\/fulltext","DOI":"10.1016\/j.dld.2009.08.002"},{"issue":"1","key":"4156_CR31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/metabo13010087","volume":"13","author":"S Stanciu","year":"2023","unstructured":"Stanciu S, Rusu E, Miricescu D, Radu AC, Axinia B, Vrabie AM, Ionescu R, Jinga M, Sirbu CA. Links between metabolic syndrome and hypertension: the relationship with the current antidiabetic drugs. Metabolites. 2023;13(1):87. https:\/\/doi.org\/10.3390\/metabo13010087. PMID: 36677012; PMCID: PMC9863091.","journal-title":"Metabolites"},{"issue":"8","key":"4156_CR32","doi-asserted-by":"publisher","first-page":"e04583","DOI":"10.1016\/j.heliyon.2020.e04583","volume":"6","author":"ME Annani-Akollor","year":"2020","unstructured":"Annani-Akollor ME, Laing EF, Addai-Mensah O, Fondjo LA, Adu EA, Owiredu EW. Population-derived cut-off for HbA1c could enhance the identification of metabolic syndrome among non-diabetic population. Heliyon. 2020;6(8):e04583.","journal-title":"Heliyon"},{"key":"4156_CR33","doi-asserted-by":"publisher","first-page":"915394","DOI":"10.3389\/fendo.2022.915394","volume":"13","author":"M Ying","year":"2022","unstructured":"Ying M, Hu X, Li Q, Dong H, Zhou Y, Chen Z. Long-term trajectories of BMI and cumulative incident metabolic syndrome: A cohort study. Front Endocrinol (Lausanne). 2022;13:915394. https:\/\/doi.org\/10.3389\/fendo.2022.915394. PMID: 36568079; PMCID: PMC9773063.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"4156_CR34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/PEP.0000000000000589","volume":"31","author":"SC Stolzman","year":"2019","unstructured":"Stolzman SC, Skelton J, Harkins A, Hoeger Bement M. Does weight status impact metabolic health in adolescents when controlling for physical fitness?? Pediatr Phys Ther. 2019;31(2):134\u201340.","journal-title":"Pediatr Phys Ther"},{"issue":"9","key":"4156_CR35","doi-asserted-by":"publisher","first-page":"e008204","DOI":"10.1136\/bmjopen-2015-008204","volume":"5","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Zhang T, Zhang C, Tang F, Zhong N, Li H, et al. Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified bayesian network in a Chinese population. BMJ Open. 2015;5(9):e008204.","journal-title":"BMJ Open"},{"issue":"1","key":"4156_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.7570\/jomes21062","volume":"31","author":"VGR Gangireddy","year":"2022","unstructured":"Gangireddy VGR, Pilkerton C, Xiang J, Tinajero R, Ashcraft AM. Hepatic fibrosis and steatosis in metabolic syndrome. J Obes Metab Syndr. 2022;31(1):61\u20139.","journal-title":"J Obes Metab Syndr"},{"issue":"7","key":"4156_CR37","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","volume":"110","author":"P Kasper","year":"2021","unstructured":"Kasper P, Martin A, Lang S, K\u00fctting F, Goeser T, Demir M, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110(7):921\u201337.","journal-title":"Clin Res Cardiol"},{"issue":"6","key":"4156_CR38","doi-asserted-by":"publisher","first-page":"978","DOI":"10.2337\/dc23-1937","volume":"47","author":"Y Shang","year":"2024","unstructured":"Shang Y, Grip ET, Modica A, Skr\u00f6der H, Str\u00f6m O, Ntanios F, et al. Metabolic syndrome traits increase the risk of major adverse liver outcomes in type 2 diabetes. Diabetes Care. 2024;47(6):978\u201385.","journal-title":"Diabetes Care"},{"issue":"1","key":"4156_CR39","doi-asserted-by":"publisher","first-page":"17258","DOI":"10.1038\/s41598-019-53947-z","volume":"9","author":"J Lee","year":"2019","unstructured":"Lee J, Cho YK, Kang YM, Kim HS, Jung CH, Kim HK, et al. The impact of NAFLD and waist circumference changes on diabetes development in prediabetes subjects. Sci Rep. 2019;9(1):17258.","journal-title":"Sci Rep"},{"issue":"5","key":"4156_CR40","doi-asserted-by":"publisher","first-page":"101896","DOI":"10.1016\/j.clinre.2022.101896","volume":"46","author":"A Boulouta","year":"2022","unstructured":"Boulouta A, Aggeletopoulou I, Kanaloupitis S, Tsounis EP, Issaris V, Papantoniou K, et al. The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience. Clin Res Hepatol Gastroenterol. 2022;46(5):101896.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"4156_CR41","doi-asserted-by":"publisher","unstructured":"Wisniewski A, DeLouize AM, Walker T, Chatterji S, Naidoo N, Kowal P et al. Sustained metabolic dysregulation and the emergence of diabetes: associations between HbA1c and metabolic syndrome components in Tunisian diabetic and nondiabetic groups. J Physiol Anthropol [Internet]. 2024 Dec 1 [cited 2025 Jun 25];43(1):1\u201314. Available from: https:\/\/jphysiolanthropol.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s40101-024-00365-4","DOI":"10.1186\/s40101-024-00365-4"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04156-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04156-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04156-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T22:32:52Z","timestamp":1757370772000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04156-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4156"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04156-8","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was obtained from the Institutional Review Board (IRB) at An-Najah University, West Bank\u2013 Palestine. Participants were informed about the purpose, technique, risks, and benefits of the study, and consent was obtained from all participants prior to their involvement. Confidentiality and privacy of participants and their data was strictly maintained throughout the study as only the researchers and supervisors are able to access them. This study was conducted in accordance with the ethical principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"562"}}